Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05621408

Attention Training Technique in Treatment of Anxiety and Depression in Coronary Heart Disease Patients

Attention Training Technique in Treatment of Anxiety and Depression in Coronary Heart Disease Patients -a Randomized Controlled Trial With 6 Months Follow-up

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
64 (estimated)
Sponsor
Vestre Viken Hospital Trust · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Anxiety and depression are associated with work disability, lower participation rate in cardiac rehabilitation and unfavourable life style changes following a coronary heart disease (CHD) event. The prevalence of clinically significant symptoms of depression and anxiety in CHD patients has been estimated to 30-50%. Furthermore, depression and anxiety are associated with a significant increased risk of subsequent major adverse cardiovascular events and mortality in CHD patients. Psychological interventions for anxiety and depression in CHD patients have demonstrated small and uncertain effects of symptoms, and no effect on cardiovascular outcomes. Therefore, testing the effectiveness of specific psychological interventions that may affect central mechanisms for cardiovascular outcomes, has been requested. The Attention training (ATT) Study is a randomized controlled trial comparing group-attention training to wait-list control in 64 patients who experience significant anxiety and depression after a CHD event. It will also be explored whether reduction in psychological symptoms is correlated with changes in biological markers with a potential link to cardiovascular outcomes.

Conditions

Interventions

TypeNameDescription
BEHAVIORALAttention Training TechniqueAttention Training Technique is a six weeks psychological intervention provided by trained professionals

Timeline

Start date
2022-11-30
Primary completion
2024-12-20
Completion
2024-12-20
First posted
2022-11-18
Last updated
2024-05-16

Locations

2 sites across 1 country: Norway

Source: ClinicalTrials.gov record NCT05621408. Inclusion in this directory is not an endorsement.